I hesitate to bring this up but does anyone else find the
I hesitate to bring this up but does anyone else find the trial numbers suspicious?
Looking at them, I come to them with the conviction that I stated in msg 81679 - "Make no mistake - all recipients of Leronlimab benefited to some degree, even the ones too far gone to survive!" Not all of the trial patients were in the ICU because of Cytokine Storm but I know that Leronlimab shut down RANTES in everyone who got it! By some metric, Leronlimab helped everyone!
So why aren't we seeing the results we were expecting to see in these CD12 numbers? I'm not talking about primary and secondary endpoints and p values. I was expecting to see the result we saw from the first uses of Leronlimab with Seethamraju, Lang, Agresti and Reknor. Sure SOC has gotten better but NEWS type scores, Ordinal Scale numbers should have been better, much better in my opinion.
We had some large improvement by some individuals so of course the Ordinal Scale numbers would go up but if the numbers of all patients who got Leronlimab went up, we should see these number much higher. What happened to individual patients is lost in the average totals reported in the 8K report.
If something suspicious was going on, it would have shown itself in the individual cases where, after injection with Leronlimab, there was no patient improvement at all. We may not have used the metrics in the trial to show this but that result would have been there. Blood tests would have been nice but just the clinical outcomes should have been obvious.
This issue really worries me because if something funny went on with the CD12 trials, it could go funny with this CD16 trial. What are the checks and balances? Are we totally sure that those who were supposed to get Leronlimab really did get Leronlimab?
Can we compare the Ordinal (NEWS) type scores of those who got Leronlimab thru OLE and eINDs with those in the CD12 trial? Can we insist on blood tests after Leronlimab administration in the CD16 trial? We can't afford any screw-ups!
3
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Revamping AI in Veterinary Practices Out there in San Diego, Vetology's been rolling up its sleeves and getting down to brass tacks with a complete do-over of their AI classifiers. They’ve rebuilt all 94 of them, every last one, on a brand-new architecture. No small task, this overhaul stretched from June to August and it wasn't just paint and polish but a whole new...
Continue Reading
Revolutionizing Viticulture with Data In today's wild world, climate change isn't just shifting weather patterns—it's upending the age-old map of wine-making regions. We've got a new player on the field: the World Winery Map. It's digital, massive, and it’s shaking things up for winemakers and grape enthusiasts alike. This platform covers a staggering 4.3 million...
Continue Reading
Gaming Illuminates Pathways to Literacy and Community Trust me, when an indie game publisher like Kobold Press makes waves, it's worth paying attention. They've carved a niche in the roleplaying world by marrying traditional game elements with valuable educational tools. The thrill of the game goes beyond rolling dice; it's a ticket to improving literacy, arithmetic, and...
Continue Reading
Unpacking Bascom's Jasmine Acquisition In a market that's been more slippery than a greased pig, Bascom Group's move buying up Jasmine Apartments is capturing some eyes. Situated in North Dallas, this 370-unit complex ain't just another brick in the wall—it's Bascom's 42nd entry into Texas, reinforcing their knack for sniffing out deals others might tiptoe around,...
Continue Reading
End of an Era: Warren Buffett's Retirement Warren Buffett—there's a name that's echoed through the halls of investment for decades. Today, he's pulling down the curtain as Chairman of Berkshire Hathaway (NYSE: BRK). No fanfare, just a nod to the inevitable with his classic, humor-tinged confession: 'Father Time always wins.' Can’t argue with the man who’s seen the...
Continue Reading
Radon Mitigation: A Critical Measure for Home Safety Homeowners, you're probably aware of the ticking health time bomb known as radon. Not just an annoying gas, this colorless, odorless beast lurks quietly, threatening family health if not managed right. Mitch Kelley, a specialist in radon testing with Basement Solutions in Mankato, Minnesota, lays out a no-fuss guide to...
Continue Reading
AI's Increasing Role: A Double-Edged Sword for Leaders Hey, the tech overlords remind us once again—the future doesn't wait for anyone to catch up before it bulldozes forward. Info-Tech Research Group has sounded the alarm on AI agents muscling their way into product decisions without any clear nod from the human corner office. Blurring Lines of Accountability The...
Continue Reading
Young Artists Called to Inspire a Cancer-Free World What's the first image that pops into your head when you think of a world free from cancer? That's the magic question on deck for this year's Youth Art Contest by Debbie's Dream Foundation. Imaginations are set to run wild as the competition opens its gates to artists under 18, calling for visions splashed across...
Continue Reading
Award-Winning Tool Headlines 2026 Beauty Scene There's a shake-up in the world of hair tools, folks. Bellissima's Diffon Supreme has snagged a 2026 Allure Best of Beauty Award for its prowess in taming the curly, wavy, and coily strands we all crave to manage. Performance Meets Innovation in Bellissima's Latest Let's not beat around the bush. The Diffon Supreme's trump...
Continue Reading
Quantum Leap: Chattanooga's Bold Move So Chattanooga’s making waves again, folks. EPB just unveiled its new big shot, the IonQ Forte Enterprise quantum computer. That's right, they’ve slapped a commercial quantum computer and a networking hub together, right here in this Tennessee city. Is this a tech haven or what? Not to mention, it’s the first in America. A New...
Continue Reading
Top 5 Most Recently Viewed Articles
GGT Stock Hits a New 52-Week Low In a year characterized by market instability and economic challenges, Gabelli MultiMedia Trust (GGT) has seen its stock price fall to a new 52-week low of $4.55. This decline is revealing of broader market dynamics affecting investor sentiment and stock performance. With a market capitalization of $129.17 million and a beta of 1.26, GGT's...
Continue Reading
Bank7 Earnings Report: What Investors Should Anticipate Bank7 (NASDAQ: BSVN) is set to unveil its quarterly earnings report soon, and investors are eagerly awaiting the details. While stock prices can fluctuate based on reported earnings, guidance is often the pivotal factor that influences market reactions. Expectations Ahead of the Announcement Analysts are predicting...
Continue Reading
Squirrel Ai Unveils Innovative S20 Tablet with TCL Display Tech The latest advancement in educational technology has arrived with the Squirrel Ai S20, a cutting-edge smart learning tablet that showcases TCL's NXTPAPER display. This remarkable launch at CES signifies a leap forward in merging advanced display technology with adaptive learning capabilities. The...
Continue Reading
Addentax Group Corp. Seeks Major Bitcoin Acquisition Boost Addentax Group Corp. (Nasdaq: ATXG) has taken a bold step forward with a recent announcement regarding an acquisition that could significantly boost its presence in the cryptocurrency market. The company has entered into a non-binding term sheet to acquire up to 12,000 Bitcoins from a major independent holder,...
Continue Reading
Positive Revenue Signals from TSMC Taiwan Semiconductor Manufacturing Co. (TSMC) has recently announced a remarkable revenue increase of 33% for the month. This positive trend is encouraging for investors who are hopeful about a recovery in the smartphone market and sustained demand for AI technology. This surge in revenue highlights TSMC's crucial position in the...
Continue Reading